Celgene refiles ozanimod with FDA 1 year after regulatory snafu

celgene
The fate of ozanimod will play a role in how much Bristol-Myers ultimately pays for Celgene. (Celgene)

Celgene has refiled for FDA approval of ozanimod in multiple sclerosis. The resubmission comes one year after Celgene was rocked by a refusal-to-file notice from the FDA. 

The FDA hit Celgene with the notice a little more than 12 months ago due to shortcomings in the preclinical and clinical pharmacology parts of its package. Celgene looked to some ongoing clinical pharmacology programs for data to address the FDA’s demands but hopes of a rapid resolution to the logjam faded quickly. 

Celgene’s resubmission took a little more than a year but, as promised, the big biotech got its filing back in front of the FDA by the end of the first quarter. The timing sets Celgene up to bring the drug to market next year.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

By then, Celgene could be part of Bristol-Myers Squibb. The fate of ozanimod will play a role in how much Bristol-Myers ultimately pays for Celgene. Having offered $57 a share in cash for Celgene at one point in the negotiations, Bristol-Myers ultimately signed off on $50 a share and a further $8 a share if FDA approves ozanimod, JCAR017 and bb2121 by the end of 2020.

Celgene still has a long way to go to pull off that triple approval but getting the ozanimod filing back in front of the FDA clears the first small hurdle. 

The original filing for FDA approval of ozanimod was a low point for Celgene in a bad period for the company. The regulatory misstep hurt Celgene’s reputation, further pressured its share price and enabled Novartis to steal a lead in the race to bring a SP1 drug to market, denting the prospect of ozanimod living up to its billing as a big blockbuster. And in the aftermath, Celgene’s Nadim Ahmed laid the blame for the snafu at Receptos’ door.

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.